© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Macitentan came out of an era marked by the search for safer and more effective treatments for pulmonary arterial hypertension (PAH). Early therapies for PAH, like prostacyclins and basic endothelin receptor antagonists, did not always hit the mark for either tolerability or convenience. As researchers saw the limitations in these drugs, teams at Actelion in Switzerland got to work refining the chemical structure and receptor selectivity. Their extensive screening led to Macitentan, which blocks both ETA and ETB endothelin receptors. These advances relied on a deeper grasp of the endothelin pathway, and each molecule designed in the lab reflected lessons from previous efforts with bosentan and ambrisentan. By the early 2010s, Macitentan had secured regulatory approval based on strong clinical data showing benefits in slowing disease progression and reducing hospitalizations for PAH patients.
Macitentan does more than just offer another option for PAH. It gives patients a once-daily oral therapy that has fewer liver side effects compared to some earlier options like bosentan. In genuine real-world use, Macitentan often fits better into complex regimens, since it doesn’t interact heavily with other drugs. Busy clinics and patients managing multiple conditions see this as a major advantage. Hospitals and pharmacies, keeping a close eye on safety profiles, have made the switch to Macitentan thanks to its consistent results and clear benefits documented in the SERAPHIN trial.
Macitentan comes as a white to off-white crystalline powder, known for dissolving well in organic solvents and poorly in water. The chemical structure, featuring a bulky, aromatic backbone and sulfonamide group, gives it enough stability to keep its potency under normal storage. It holds up under moderate heat and humidity, though the recommended storage conditions favor cool and dry environments. Manufacturers take extra care at every stage, right from handling to packaging, because the molecular configuration affects both shelf life and formulation possibilities.
Pharmaceutical-grade Macitentan comes at high purity, usually above 99% as verified by HPLC tests. Each batch undergoes rigorous quality checks for residual solvents, heavy metals, and related substances. Labels on commercial packages include not just batch numbers, expiry dates, and barcodes but also detailed storage and usage information to support robust pharmacovigilance. Tablets get color-coded for strength—often 10 mg is deep yellow for better bedside identification. Technician sheets break down major analytical data, including melting point (around 188–194 °C), logP values, and suggested analytical methods.
Macitentan synthesis combines industrial-scale organic chemistry with painstaking purification. Starting from tailored aromatic precursors, chemists form key intermediates through multi-step reactions involving nitration, sulfonation, and amide formation. Each reaction gets closely monitored for pH, temperature, and yield. Intermediate purifications use solvent extractions and chromatography to remove reaction byproducts. During the final steps, the core structure undergoes precise cyclization and functional group modifications that deliver high yields. After synthesis, final salt formation and crystallization give the desired polymorphic form for tablet-making.
Small tweaks in the main aromatic ring or sulfonamide linkage during R&D inspired Macitentan’s current molecular identity. Chemists have experimented with substitutions at various positions to influence receptor binding, metabolism, and solubility. Some analogues showed stronger activity but also higher toxicity; the development process zeroed in on modifications that kept liver exposure low but still maintained strong affinity for both endothelin receptor types. Rare side reactions—like oxidative degradation or light-induced rearrangement—taught formulators the right conditions for compounding and storage. Scientists now experiment with prodrugs and new salt forms, hoping to refine absorption and reduce pill size for future generations.
Macitentan appears under several synonyms in chemical catalogs and regulatory filings: ACT-064992, Opsumit® (the commercial name under Janssen/Actelion), and UTVR. It may show up as N-[5-(5-bromopyridin-2-yl)-2-[[4,6-dimethylpyrimidin-2-yl]oxy]benzyl]-N-propylsulfamide in IUPAC listings. These variations sometimes trip up procurement teams, making careful label review essential. Research suppliers catalog it by both chemical registry numbers and trade names, reflecting its dual role in clinical and laboratory settings.
Macitentan ranks as a hazardous material in its raw form, with powdered dust requiring gloves, goggles, and well-ventilated hoods for safe handling. Occupational health protocols in API manufacturing keep airborne particulates below strict limits. Tablet forms carry less risk, but regular training ensures pharmacy staff stick to protocols on counting, crushing, and disposal. Regulatory guidelines emphasize routine lab surface checks and waste tracking. Consumer-level standards require pregnancy warnings: Macitentan causes fetal harm, so strict REMS (Risk Evaluation and Mitigation Strategy) programs track every patient and prescriber across the supply chain.
Doctors prescribe Macitentan for adults with confirmed WHO Group I PAH, both newly diagnosed and those failing older regimens. Its use sometimes extends to special cases out of label, under research protocols for chronic thromboembolic pulmonary hypertension (CTEPH) and digital ulcer prevention in scleroderma. Transplant centers take notice of its dosing stability, managing patients with complicated drug combinations. Research hospitals and rare disease consortia run multi-year case series, learning about interactions with anticoagulants and boosting the evidence pool for even broader indications. In all these roles, Macitentan stands as both a core therapy and a springboard for new PAH combo regimens.
Since the landmark SERAPHIN and MERIT-1 studies, research laboratories have kept pushing the boundaries, mapping how Macitentan works in diverse patient groups and across genetic backgrounds. Pharmaceutical teams invest in new delivery formats such as long-acting injectables, hoping to help patients who struggle with daily tablets. Scientists at university research centers investigate its effect on cardiac fibrosis, autoimmune complications, and systemic endothelial dysfunction. Ongoing clinical trials look at long-term outcomes, aiming to tie molecular markers in the blood to response rates and guide tailored therapy. Collaboration across academic, clinical, and industrial sites brings faster answers, letting frontline doctors bring fresh findings straight to the bedside.
Every new drug faces tough safety screens, and Macitentan is no exception. Preclinical data show potential for liver enzyme elevations, but fewer cases of severe liver injury than earlier ERAs. Monitoring protocols track liver function for anyone on therapy, and post-marketing surveillance studies look for rare side effects like anemia and edema. Reproductive toxicity means strict birth control for female patients. Animal studies suggest dose-dependent risks at very high exposures; findings influence dosing decisions and special warnings on the label. Real-world registries continue to capture long-term safety, helping public health experts build nuanced risk profiles that shape patient counseling and follow-up routines.
Macitentan, as a chemical and as a drug, sits at a crossroads for innovation in PAH and beyond. New research pipelines explore its analogues for rare forms of fibrosis, chronic kidney disease, and even certain cancers where endothelin pathways play a role. Biotech startups are exploring modified-release beads, dissolvable films, and even inhaled nano-formulations that build on Macitentan’s core structure. As genomic data links specific mutations with endothelin overactivity, targeted approaches may mean faster, precision-matched therapy. Regulatory bodies and academic journals call for more real-world data, hoping to fine-tune dosing and spot subtle side effects early. Looking ahead, Macitentan’s story reflects not just a single triumph over PAH, but a case study in how relentless chemical tinkering, tough clinical trials, and deep teamwork across continents lead to better patient lives and smarter medicine.
Imagine shortness of breath turning simple tasks—like walking across a room—into a challenge. For people living with pulmonary arterial hypertension (PAH), this isn’t just a bad day; it’s everyday life. PAH means the blood vessels in the lungs thicken and tighten over time, pushing up blood pressure in the lungs and putting strain on the heart. This rare disease often strikes adults between 30 and 60, and many face years searching for answers before getting the right diagnosis. The sense of relief after finding out they are not “just out of shape” doesn't erase the fear: untreated PAH carries a real risk to life. That’s where Macitentan steps in.
Macitentan works by blocking certain substances in the lungs that cause vessels to narrow. These substances, called endothelins, squeeze blood vessels and boost pressure inside them. The pill helps widen those vessels, making it easier for blood to get through and for the heart to do its job. Evidence from clinical studies shows patients taking Macitentan face fewer trips to the hospital and remain more active longer than people who don’t. The standout trial, SERAPHIN, followed hundreds of PAH patients, revealing those using Macitentan lived longer without their disease getting worse. That matters for patients who want to plan their next birthday—not just their next treatment.
Doctors have aimed to slow PAH using several medications, but not all options give the same results. Some older drugs control symptoms but bring risks that force patients to quit them. Macitentan has shown a better side effect balance; fewer liver problems, less swelling, and once-daily dosing make sticking to therapy less of a struggle. For many patients, picking up a Macitentan prescription is a chance to take back some control from their disease. My own time helping a family friend living with PAH showed me how much hope people pin on each new therapy. Watching her catch her breath less often gave her—not just the doctors—confidence in the medicine.
It’s not a pill for every lung-related problem. Macitentan treats PAH after careful testing and evaluation by specialists, often in a hospital setting. No medicine promises a cure, and those using it need regular check-ups. Women consider their options closely, as Macitentan can cause serious birth defects. Open conversations about pregnancy plans often shape a patient's medical choices, and for some, the demands of regular blood tests and potential drug interactions make day-to-day life a balancing act. The high cost of this new drug also causes headaches for those without strong insurance.
Real progress rests on broader access to life-changing drugs, better education for both physicians and patients, and more research funding. Many doctors go years without seeing a PAH patient, so quicker referrals to specialists would mean faster starts with proven therapies. Insurers playing fair on coverage would remove a lot of the “red tape” stress. Research moves on: new combinations and even personalized approaches seem possible as we learn more about the genetic underpinnings of the disease. Supporting funding, spreading awareness, and listening to patients can turn hope into real health gains for those living with PAH.
Macitentan helps many adults who live with pulmonary arterial hypertension breathe a little easier. It eases the blood flow through narrowed vessels, making daily life less breathless. Still, like with any strong medication, not everyone feels fine while taking it. I’ve spoken to folks and read stories in patient forums, and several issues pop up more than others.
The experience often starts with a headache. These headaches can last for days and sometimes feel dull but constant. Many patients mention feeling tired—sometimes this fatigue feels heavier than anything they ever dealt with before, like wading through thick mud just to get through a workday. Swollen ankles and feet come up, too. Fluid just doesn’t move as well, and it leaves some people squeezing into shoes that fit fine before.
Nosebleeds are another quirk with macitentan. It doesn’t happen to everyone, but those who deal with it say it usually hits when they least expect it. Cough and stuffy nose tag along more than one would hope, making things more annoying during allergy season. Liver changes can show up in tests, which doctors track by checking bloodwork. Few people actually feel pain or notice something off right away, which stresses the importance of regular check-ins.
Doctors keep a sharp eye out for signs of anemia with macitentan. Blood counts can dip, and that means less oxygen moving through the body. Symptoms might sneak up as shortness of breath or feeling dizzy when standing. Bloodwork tells the truth, and sometimes folks need to adjust the plan.Breathing troubles, rashes, or swelling in the throat rarely show up, but these signs point to something more serious and need quick action.
No one likes lining up for blood draws, but regular monitoring makes a real difference. It protects folks from hidden risks that don’t show up with aches and pains. Doctors commonly check liver enzymes and blood counts to spot problems early. Some people find side effects fade after a few weeks. Others need lifestyle shifts, like cutting down on salty snacks to reduce swelling or leaning on compression socks.
Talking openly with healthcare teams changes the odds. Honest conversations help catch problems fast. If something feels off—maybe headaches stick around, swelling spreads, or everyday walking feels harder—it’s time to pick up the phone or mention it during a visit. Doctors can tweak the dose, order a new test, or suggest a different approach.
Staying educated makes a difference, too. Reading up on what to expect and asking questions arms patients with the info they need to keep things in check. Having a family member watch for changes provides an extra layer of safety when tiredness or dizziness makes it hard to keep track.
Every person deserves to feel safe while treating a serious illness. Macitentan brings relief for many, but side effects mean people need tools to stay on top of their health. Honest reporting and close follow-ups help patients get the benefits without being caught off guard by the bumps along the way.
Macitentan comes into play for people with pulmonary arterial hypertension, a condition that squeezes a lot of energy from daily life. Doctors prescribe this tablet to help lower the blood pressure in your lungs, allowing your heart to work less hard. What often gets missed in long pamphlets is the value of sticking to a practical, real-world routine while using this medicine.
With Macitentan, swallowing the pill whole with a drink of water, once a day at about the same time, matters much more than most realize. Cutting, crushing, or breaking it destroys its slow-release properties. I learned through working with a support group for rare lung diseases that routines save energy for other important things in your day. Missing a dose here and there won’t always cause instant problems, but regularity ramps up your chance to breathe better and see benefits over time.
Some medicines demand strict rules around mealtimes, but Macitentan keeps things simple. Food doesn’t slow it down or speed it up in your system. Take it with breakfast, lunch, or even a late-night snack if that’s when you remember best. Mixing it up with grapefruit or grapefruit juice can cause issues, though. That fruit blocks the breakdown of Macitentan in your body, leading to greater risk for side effects. I’ve seen friends trip up on this detail because they didn’t connect fruit juice with medication reactions.
Other medicines, herbs, or supplements can compete with Macitentan too. This isn’t always obvious. Some antibiotics, antifungals, and even HIV treatments use the same metabolic pathways—this causes levels to climb or drop without warning. Every time your doctor suggests a new pill or a supplement, make the connection and ask if it changes how Macitentan works.
Side effects sometimes sneak up even if you follow every instruction perfectly. Swollen ankles, shortness of breath, or signs of liver trouble are worth mentioning at every visit. Never tough it out or skip blood tests, especially during the first few months. Big studies show that even subtle shifts in liver function or red blood cell counts can snowball into real trouble if ignored. Bringing up every symptom—no matter how small—keeps you and your doctor ahead of problems.
It sounds easy on paper to remember a once-a-day medicine, but life’s distractions get in the way. Setting a phone alarm worked for a friend of mine who always forgot pills in the evening. Pill organizers, visual reminders on the refrigerator, or task apps on smart devices all create practical checkpoints. If cost or insurance hurdles crop up, ask for help early. Some pharmaceutical companies offer assistance programs, and social workers in the clinic can connect you to support.
Macitentan isn’t just about the tablet. It’s about consistent habits, honest conversations with your care team, and troubleshooting real-world obstacles. The energy saved adds up, not just in breathing easier, but in freeing your mind for what matters most each day. Staying informed and organized isn’t just helpful—it truly shapes your road to better health.
Pregnancy calls for tough choices about medicines. It’s not just about the mother. The developing baby reacts to every small change, especially chemicals. Macitentan treats pulmonary arterial hypertension, a serious heart and lung condition. During pregnancy, every prescription gets another look. I remember family and friends who reached out to doctors for advice about drugs that seemed harmless before they got pregnant. Choices suddenly carried weight for two.
Macitentan targets blood vessels, relaxing them to lower lung pressure. This benefit comes with a cost. Experts and government health agencies warn about the risk of birth defects. Studies show this medicine can cause serious harm to unborn babies. Problems with the heart and jaw in animal studies triggered a strong warning from regulators. A single dose caused lasting changes—nothing gets shrugged off as “just one pill.” This builds a case doctors and patients shouldn’t ignore.
Doctors, including specialists in cardiovascular and maternal health, routinely advise against Macitentan during pregnancy. The U.S. Food and Drug Administration classifies this drug as unsafe for expectant mothers. In my research, I’ve seen regulators stress that women who can become pregnant must use reliable birth control before starting treatment, and monthly pregnancy tests form part of the care plan. “It’s about prevention,” a Texas cardiologist once told me. “Once the damage is done, we don’t get a do-over.”
Nobody wants to gamble with a child’s life. That sense of worry shows up again and again in patient forums and support groups for mothers with pulmonary hypertension. Some women choose to stop the medicine and risk their own health, hoping for stable blood pressure through other means. Others search high and low for safer alternatives or seek a second opinion from specialists. Medication safety becomes a community effort. Support from family and clinicians can help mothers weigh the risk of untreated disease against the damage drugs might cause.
Switching drugs isn’t simple, but it’s not impossible. Doctors and researchers point patients toward medicines that have less history of causing birth defects. Sometimes these options don’t work as well, or they come with new side effects. Supportive therapies—oxygen, lifestyle changes, closely watched exercise—play a bigger role in pregnancy for women with heart and lung disease. In tough cases, specialists in maternal-fetal medicine team up with cardiologists to draft a careful plan. This collaboration helps women chart a path forward without Macitentan.
Macitentan stands off-limits for pregnancy, not just because of policy but real risks shown in the lab and echoed in clinical experience. Honest conversations, clear safety nets like strict contraceptive use, and regular pregnancy tests shape care for women who still need strong medicine for their disease. If someone discovers they’re pregnant while taking Macitentan, doctors act fast. They stop the medicine and offer support and next steps, repeating a clear message: protecting a new life means taking bold steps, even if it means giving up an effective treatment for a while.
In the end, health choices during pregnancy never feel easy. Still, the information about Macitentan is sharp and clear. Avoiding it gives a future child a better chance for a healthy start. Informed, tough choices matter in every pregnancy, and experts can help map out the best next steps.
Anyone dealing with pulmonary arterial hypertension likely recognizes macitentan as a name that comes up at doctor’s visits. Taking it helps manage the tightness in pulmonary arteries, easing pressure off the heart. Doctors like to use macitentan because it fits well into many treatment plans, but they always stop and double-check what other medicines a person might have at home. No two bodies react exactly the same, so mixing drugs calls for careful thought and honest talk between patients and doctors. Skipping over that step can cause real harm.
Macitentan relies on liver enzymes (especially CYP3A4), which work much like gatekeepers. Some drugs—think ketoconazole or ritonavir—can block that enzyme’s work, changing how much macitentan stays in the bloodstream. Someone taking those medicines may wind up with higher levels of macitentan than their body expects, which increases the risk of side effects like liver problems or low blood pressure. Grapefruit juice also throws a wrench in the works by affecting the same enzyme, but few folks realize it. Doctors stress the importance of honest answers on patient forms for just that reason.
In my own circle, stories stick out of folks who assumed supplements or common antibiotics wouldn’t matter. One friend started on clarithromycin for a stubborn chest infection, and her doctor caught the issue at the pharmacy’s warning screen. Stopping to adjust the treatment saved her from a week of nausea and fatigue. Clinics and pharmacies now flag these combinations, and it’s not just busywork. Official prescribing information lists strong CYP3A4 inhibitors and inducers as medicines to avoid or adjust. That includes some HIV medicines, certain antifungals, and even the anti-seizure drug carbamazepine, which can make macitentan less effective—and nobody wants to lose precious ground against pulmonary hypertension.
You’d think a short conversation at the appointment solves everything, but people forget to mention over-the-counter allergy pills, herbal teas, or changes in their daily vitamin lineup. Saint John’s Wort, often sold as a mood booster, can lower macitentan’s effectiveness. Without proper warning, someone could feel worse, then blame the medicine instead of the real culprit. That experience erodes trust and can force doctors to chase symptoms they could have avoided in the first place.
No one likes to lug a shopping bag of prescriptions to every appointment, but keeping an up-to-date medicine list can change the game. Most clinics want a full list—even the seemingly harmless stuff from natural food stores. Clear habit, clear records. Encouraging patients to stay honest isn’t just about box-ticking; it stops dangerous surprises. Family and friends who help with pills should join the conversation, because two sets of eyes catch more mistakes than one.
Pharmacies already use software alerts to flag risky combinations. Hospitals invest in education for both prescribers and patients. Real progress comes from making conversations about drug interactions routine and judgment-free. Changing a prescription or taking a safer route doesn’t mean blame—it means teamwork and respect for what the human body handles every day.
Anyone starting macitentan should ask questions—every time a new pill enters the picture. Small steps, like checking labels or sitting down for a few minutes with a pharmacist, keep everyone safer. Pulmonary hypertension brings enough challenges; drug interactions shouldn’t add to the list. Lean on professionals and remember that honesty in health care pays the best dividends.
| Names | |
| Preferred IUPAC name | N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide |
| Other names |
Opsumit |
| Pronunciation | /ˌmæs.ɪˈtɛn.tæn/ |
| Identifiers | |
| CAS Number | 1077615-22-8 |
| 3D model (JSmol) | `"3D model (JSmol)" string for Macitentan: C1CN(CCN1C2=CC=CC=C2)C3=NN(C4=CC=CC=C34)C(=O)NC5=CC=CC=C5` |
| Beilstein Reference | 2742306 |
| ChEBI | CHEBI:70768 |
| ChEMBL | CHEMBL2103889 |
| ChemSpider | 7846588 |
| DrugBank | DB08916 |
| ECHA InfoCard | ECHACard: 100000193413 |
| EC Number | EC 4.2.1.1 |
| Gmelin Reference | 1379777 |
| KEGG | D09318 |
| MeSH | D000068878 |
| PubChem CID | 16005650 |
| RTECS number | RV6V7R73L9 |
| UNII | G5136WH19X |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C19H20Br2N6O4S |
| Molar mass | 586.715 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.3 g/cm³ |
| Solubility in water | Sparingly soluble in water |
| log P | 2.65 |
| Acidity (pKa) | 4.74 |
| Basicity (pKb) | pKb = 3.66 |
| Magnetic susceptibility (χ) | -23.7e-6 cm^3/mol |
| Refractive index (nD) | 1.555 |
| Dipole moment | 4.62 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 266.4 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -8755 kJ/mol |
| Pharmacology | |
| ATC code | C02KX04 |
| Hazards | |
| Main hazards | Suspected of damaging the unborn child. |
| GHS labelling | GHS labelling: Signal word: Warning. Hazard statements: H361 - Suspected of damaging fertility or the unborn child. Precautionary statements: P201, P202, P280, P308 + P313, P405, P501. Pictograms: GHS08 (Health hazard). |
| Pictograms | hepatotoxicity|cyp|pregnancy|pulmonary_hypertension |
| Signal word | Warning |
| Hazard statements | H360: May damage fertility or the unborn child. |
| Precautionary statements | Keep out of the reach and sight of children. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Lethal dose or concentration | LD50 (rat, oral): >2000 mg/kg |
| LD50 (median dose) | > 2000 mg/kg (rat, oral) |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Macitentan: "No OSHA PEL established |
| REL (Recommended) | 40 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Ambrisentan Bosentan Darusentan Sitaxentan |
